Tempus is a technology company that uses genomic sequencing, clinical data, and machine learning to provide personalized cancer care. They offer a platform that analyzes vast amounts of molecular and clinical data to help doctors make more informed treatment decisions.
Tempus was founded in 2015 by Eric Lefkofsky.
In 2016, Tempus raised $30 million in Series C funding.
In 2018, Tempus partnered with the University of Chicago Medicine to provide personalized cancer treatment options.
In 2019, Tempus received FDA clearance for its next-generation sequencing assay, enabling it to provide molecular information for patients.
In 2020, Tempus launched its COVID-19 test that provides results in less than 24 hours.
As of 2021, Tempus works with over 70% of National Cancer Institute-designated cancer centers in the United States.
Foundation Medicine is a molecular information company that offers comprehensive genomic profiling tests for cancer patients. They aim to help doctors make personalized treatment decisions.
Guardant Health provides liquid biopsy tests that detect cancer-related somatic mutations in the bloodstream. Their tests help in personalized treatment selection and monitoring of cancer patients.
Grail is a healthcare company that focuses on early cancer detection through blood-based testing. They develop technology to identify multiple types of cancer at earlier stages, improving the chances of successful treatment.
Tempus xE is a comprehensive genomic profiling test that analyzes DNA, RNA, and proteins from a patient’s tumor. It provides molecular information that helps in identifying targeted treatment options for cancer patients.
Tempus O is a liquid biopsy test that detects cancer-related mutations in the bloodstream. It provides non-invasive monitoring of tumor mutations, allowing doctors to track treatment response and make adjustments if needed.
Tempus EMR is a platform that integrates electronic medical records (EMRs) and molecular data. It enables physicians to access and analyze comprehensive patient information, leading to more personalized treatment plans.
Tempus is a technology company that utilizes genomic sequencing, clinical data, and machine learning to improve personalized cancer care.
Tempus analyzes vast amounts of molecular and clinical data to provide doctors with valuable insights for making more informed treatment decisions.
Tempus xE is a comprehensive genomic profiling test that analyzes DNA, RNA, and proteins from a patient’s tumor to identify targeted treatment options.
Tempus O is a liquid biopsy test that detects cancer-related mutations in the bloodstream. It allows for non-invasive monitoring of tumor mutations.
Yes, Tempus offers Tempus EMR as a platform that integrates electronic medical records (EMRs) and molecular data for more personalized treatment planning.